Please assess the completion status of the following clinical trial:

Trial Title: Immunogenicity and Safety of PCV13 and Fluad in Adults Aged ≥60 Years

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adults aged ≥60 years who signed the informed consent~Exclusion Criteria:~* Previous pneumococcal vaccine recipients~* Egg allergy~* History of serious adverse event after vaccination,~* any acute disease or infection~* History of neurological symptoms or signs~* Impairment of immune function or immunosuppressant use~* Bleeding diathesis~* Fever (defined as axillary temperature ³38.0°C) within 3 days (prior to Visit 1)

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- PCV13 and Fluad (Type: ACTIVE_COMPARATOR): 437 concomitant Fluad-PCV13 recipients: one dose of each vaccine administered on Day 0
- Fluad alone (Type: ACTIVE_COMPARATOR): 437 Fluad recipients: one vaccine injection administered on Day 0
- PCV13 alone (Type: ACTIVE_COMPARATOR): 437 PCV13 recipients: one vaccine injection administered on Day 0

Based on this trial design, predict the completion outcome and termination type (if applicable).